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Abstract: Terrestrial plants have proven to be a prolific producer of clinically effective 
antimalarial drugs, but the antimalarial potential of seaweeds has been little explored. The 
main aim of this study was to assess the in vitro chemotherapeutical and prophylactic 
potential of the extracts of twenty-three seaweeds collected from the south coast of 
England against blood stage (BS) and liver stage (LS) Plasmodium parasites. The  
majority (14) of the extracts were active against BS of P. falciparum, with brown seaweeds 
Cystoseira tamariscifolia, C. baccata and the green seaweed Ulva lactuca being the most 
active (IC50s around 3 μg/mL). The extracts generally had high selectivity indices (>10). 
Eight seaweed extracts inhibited the growth of LS parasites of P. berghei without any 
obvious effect on the viability of the human hepatoma (Huh7) cells, and the highest 
potential was exerted by U. lactuca and red seaweeds Ceramium virgatum and Halopitys 
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incurvus (IC50 values 14.9 to 28.8 μg/mL). The LS-active extracts inhibited one or more 
key enzymes of the malarial type-II fatty acid biosynthesis (FAS-II) pathway, a drug target 
specific for LS. Except for the red seaweed Halopitys incurvus, all LS-active extracts 
showed dual activity versus both malarial intracellular stage parasites. This is the first 
report of LS antiplasmodial activity and dual stage inhibitory potential of seaweeds. 
Keywords: seaweed; marine alga; malaria; Plasmodium; malaria prophylaxis; fatty acid 
biosynthesis; liver stage; blood stage 
 
1. Introduction 
Malaria, a vector-borne disease caused by single-celled eukaryotic parasites from the genus 
Plasmodium, remains a major cause of global morbidity and mortality. According to World Malaria 
Report (2012), there were 219 million cases of malaria in 2010 and an estimated 660,000 deaths [1]. 
The disease is most prevalent in two continents, namely Africa and Asia, and the former is the most 
affected where approximately 90% of all malaria deaths occur [1]. Although the mortality rate has 
decreased in the last decade, the disease remains widespread in most endemic areas. The emergence of 
multiple drug resistance to front-line antimalarial drugs, including artemisinins, highlights the urgent 
need to identify new drugs from previously untapped sources. 
The eradication or control of malaria has been more challenging than any other parasitic disease. 
One major reason for this is the complex life cycle of the parasite, involving two hosts (human and 
mosquito), three life stages [liver stage (LS), blood stage (BS) in human and mosquito stage (MS)] and 
both asexual and sexual multiplication. Infection in the human host begins when sporozoites are 
injected by the Anopheles mosquito during its blood meal. They migrate to the host liver where they 
multiply as LS (also called as exo-erythrocytic) forms during an asymptomatic incubation period of 
generally a week, before emerging in the blood stream and invading erythrocytes (BS). The constant 
and rapid replication cycle (1–2 days) of these merozoites results in several trillion parasites in 
erythrocytes [2]. In the case of P. vivax and P. ovale, some sporozoites develop cryptic forms, the  
so-called hypnozoites, which can lie silent in the liver for years before causing a relapse [3]. 
Antimalarial drug discovery has traditionally focused on targeting asexual BS. This has two 
reasons; first, it is the stage where the clinical manifestation of the disease emerges; second, the  
in vitro and in vivo test models of BS P. falciparum parasites are well established. Although an 
obligatory stage in the life cycle of the parasite whose blockage leads to a true causal prophylaxis of 
the disease [4], the non-symptomatic LS has remained underexploited due to technical and cost-related 
difficulties. Only recently developed medium and high throughput test systems allow screening of drug 
libraries against LS Plasmodium species [5]. While most antimalarial agents target BS, relatively few 
drugs inhibit the LS parasites. Primaquine, the only FDA licensed drug used clinically, acts against LS 
of all Plasmodium species and latent stage hypnozoites. However, its tendency to cause hemolytic 
anemia, short half-life and other drawbacks limit its use widely, complicating malaria control  
efforts [3,5]. As a result of long years of research, many biological targets have been identified and are 
being used for BS malaria drug discovery. However, the LS has been truly neglected in this sense and 
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the biological target of primaquine is yet to be identified. Recently, a type II fatty acid biosynthesis 
(FAS-II) pathway, which takes place in a relict plastid like-organelle (the apicoplast) has been shown 
to be indispensable for the late stages of the LS parasites [6,7]. Disruption of the FAS-II system, which 
is different from the large associated human FAS-I system, prevents successful completion of the LS 
and the initiation of the BS infections, making FAS-II a valuable drug target for LS infections. The  
de novo FAS-II pathway was previously reported to operate in BS [8] to fuel significant research 
activity in this area. However, later transcriptome and proteome microarray studies showed that FAS-II 
genes are highly upregulated in LS [9]. Two subsequent studies [6,7] revealed the pathway to play a 
vital role only in the late phases of the LS schizogony. So it is timely to consider the potential of LS in 
current malaria intervention strategies and identify further LS targets. It is also essential to develop 
new drugs that target both mammalian developmental stages, providing true causal chemoprophylaxis 
and simultaneously curing BS malaria. 
Most of the clinically used antimalarial drugs can be tracked to a natural product obtained from a 
terrestrial plant that has been used to treat malarial symptoms traditionally. For centuries, seaweeds 
(marine algae) have been consumed as traditional medicines to treat parasitic infections in many areas 
of the world, particularly in Japan and China [10]. Kainic acid was isolated as the active principle of 
the Japanese red alga Digenea simplex and used as an antihelminthic for a long time [11,12]. The 
diverse chemistry, ready access for wild harvesting, and cultivation possibility through mariculture 
makes seaweeds realistic sources for antiparasitic drug discovery, however their true potential has 
remained underexplored. Our group has been interested in the antiprotozoal potential of seaweeds from 
various parts of the world [13–17]. In the continuation of our research interest into this area, we herein 
report the in vitro activity of twenty-three British seaweeds against BS and LS malaria parasites. In an 
attempt to identify potential targets for LS activity, inhibitory activity of the seaweed extracts has also 
been determined against three key elongation enzymes of the P. falciparum FAS-II system (PfFabI, 
PfFabG and PfFabZ), recombinantly prepared in our laboratory. 
2. Results and Discussion 
Twenty-three seaweeds (four green, eleven brown and eight red algae) were collected from the 
south coast of England. Table 1 shows their full taxonomical names, types, the exact collection sites 
and times. The seaweeds were extracted with CHCl3:MeOH mixtures, as described in the Material and 
Methods section, and used for biological activity assessments. 
Table 1. British seaweeds used in the current study. 
Seaweed Species Code Type Family Site of Collection Time of Collection 
Cladophora rupestris (L.) Kütz. CR Green Cladophoraceae Kimmeridge, Dorset April 2007 
Codium fragile (Sur.) Hariot ssp. 
tomentosoides (van Goor) Silva 
CFsT Green Codiaceae Kimmeridge, Dorset April 2007 
Ulva intestinalis L. UI Green Ulvaceae Kimmeridge, Dorset April 2007 
Ulva lactuca L. UL Green Ulvaceae Kimmeridge, Dorset April 2007 
Ascophyllum nodosum (L.) Le Jol. AN Brown Fucaceae Kimmeridge, Dorset April 2007 
Fucus serratus L. FS Brown Fucaceae Kimmeridge, Dorset April 2007 
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Table 1. Cont. 
Fucus vesiculosus L. FV Brown Fucaceae Kimmeridge, Dorset April 2007 
Cystoseira baccata (S.G.Gmel.) P.C.Silva CB Brown Sargassaceae Kimmeridge, Dorset April 2007 
Cystoseira tamariscifolia (Huds.) Papenf. CT Brown Sargassaceae Kimmeridge, Dorset April 2007 
Sargassum muticum (Yendo) Fensholt SM Brown Sargassaceae Kimmeridge, Dorset April 2007 
Laminaria digitata (Huds.) J.V. Lamour. LD Brown Laminariaceae Kimmeridge, Dorset April 2007 
Saccorhiza polyschides (Lightf.) Batt. SP Brown Phyllariaceae Kimmeridge, Dorset April 2007 
Pylaiella littoralis (L.) Kjellm. PL Brown Acinetosporaceae Emsworth, Hampshire April 2007 
Leathesia difformis (L.) Aresch. LD Brown Chordariaceae Kimmeridge, Dorset August 2007 
Dictyota dichotoma (Huds.) Lamour. DD Brown Dictyotaceae Hayling Island, 
Hampshire 
July 2007 
Osmundea pinnatifida (Huds.) Stackh. OP Red Rhodomelaceae Kimmeridge, Dorset April 2007 
Calliblepharis jubata (Good. et Woodw.) Kütz. CJ Red Cystocloniaceae Kimmeridge, Dorset April 2007 
Ceramium virgatum Roth CV Red Ceramiaceae Kimmeridge, Dorset April 2007 
Claviclonium ovatum (J.V.Lamour.) Kraft & 
Min-Thein 
ClO Red Acrotylaceae Kimmeridge, Dorset April 2007 
Halopitys incurvus (Huds.) Batt. HI Red Rhodomelaceae Kimmeridge, Dorset April 2007 
Corallina officinalis L. CoO Red Corallinaceae Seacombe, Dorset April 2007 
Porphyra linearis Grev PoL Red Bangiaceae Seacombe, Dorset April 2007 
Halurus equisetifolius (Lightf.) Kütz. HE Red Wrangeliaceae Kimmeridge, Dorset August 2007 
2.1. Blood Stage Antimalarial Activity and General Cytotoxicity of British Seaweeds 
Due to the escalating problem of drug-resistance, the seaweed extracts were tested against BS 
parasites of the multi-drug resistant K1 strain of P. falciparum. A well-established radioactive 
incorporation assay utilizing 
3
H-Hypoxanthine was employed. [18]. As shown in Table 2, the extracts 
obtained from the brown algae Cystoseira tamariscifolia (CT) and C. baccata (CB), as well as the 
green alga Ulva lactuca (UL) exerted the highest erythrocytic stage antimalarial activity with IC50 
values ranging between 3.3 and 3.8 μg/mL. The red seaweed Corallina officinalis (CoO) was also 
active (IC50 8.6 μg/mL). The potency of the other ten active extracts, i.e., green algae [Cladophora 
rupestris (CR), Codium fragile ssp. tomentosoides (CFsT) and Ulva intestinalis (UI), five brown algae 
(Fucus serratus (FS), F. vesiculosus (FV), Sargassum muticum (SM), Laminaria digitata (LD), 
Saccorhiza polyschides (SP) and two additional red algae (Osmundea pinnatifida (OP), Ceramium 
virgatum (CV)] varied from 11.8 to 18.2 μg/mL. The remaining nine extracts were completely inactive 
against BS malaria parasites at the highest test concentrations (50 μg/mL). The extracts were generally 
devoid of any cytotoxicity against mammalian L6 cells (IC50 values >90 μg/mL), a primary 
mammalian cell line derived from rat skeletal myoblasts [13–15]. Only the extracts of  
C. tamariscifolia (CT) and C. officinalis (CoO) showed low toxicity with IC50 values of 62.5 and  
88.6 μg/mL, respectively (Table 2). In any case, the selectivity indices of algal extracts (SI: IC50 value 
obtained for mammalian cells divided by the IC50 value against the parasite) were over 10, including 
those of C. tamariscifolia (CT) and C. officinalis (CoO). 
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Table 2. In vitro inhibitory activity of seaweeds against P. falciparum blood stage (BS) 
and P. berghei liver stage (LS) infections, FAS-II target enzymes and mammalian L6 cells 
(IC50 values in μg/mL). 
Seaweed Species Type BS LS PfFabI PfFabG PfFabZ L6 cells 
f
 
Cladophora rupestris Green 11.9 37.3 >50 >50 1.0 >90 
Codium fragile ssp. tomentosoides  11.8 34.6 >50 >50 13 >90 
Ulva intestinalis  18.2 >50 n.t n.t n.t >90 
Ulva lactuca  3.8 14.9 2.0 >50 7.0 >90 
Ascophyllum nodosum Brown >50 >50 n.t n.t n.t >90 
Fucus serratus  17.6 >50 n.t n.t n.t >90 
Fucus vesiculosus  15.7 >50 n.t n.t n.t >90 
Cystoseira baccata  3.4 32.6 2.3 2.0 1.4 >90 
Cystoseira tamariscifolia  3.3 49.4 37 2.8 1.3 62.5 
Sargassum muticum  18.2 >50 n.t n.t n.t >90 
Laminaria digitata  17.6 >50 n.t n.t n.t >90 
Saccorhiza polyschides  16.1 >50 n.t n.t n.t >90 
Pylaiella littoralis  >50 >50 n.t n.t n.t >90 
Leathesia difformis  >50 >50 n.t n.t n.t >90 
Dictyota dichotoma  >50 >50 n.t n.t n.t >90 
Osmundea pinnatifida Red 14.5 52.9 >50 >50 3.0 >90 
Calliblepharis jubata  >50 >50 n.t n.t n.t >90 
Ceramium virgatum  13.6 26.4 30 13 4.2 >90 
Claviclonium ovatum  >50 >50 >50 >50 2.1 >90 
Halopitys incurvus  >50 28.8 2.4 15.9 2.9 >90 
Corallina officinalis L.  8.6 >50 n.t n.t n.t 88.6 
Porphyra linearis  >50 >50 n.t n.t n.t >90 
Halurus equisetifolius  >50 >50 n.t n.t n.t >90 
Positive control  0.056 
a
 3.4 
b
 0.014 
c
 0.30 
d
 0.03 
d
 0.004 
e,f
 
Control drugs: a Chloroquine, b primaquine, c triclosan d (−)-epigallocatechin gallate, e podophyllotoxin, f from [15–17]. 
2.2. Liver Stage Activity of British Seaweeds 
Next we tested the efficacy of the seaweed extracts on LS of the rodent malaria parasite P. berghei 
by using a transgenic P. berghei parasite expressing the bioluminescent reporter protein luciferase to 
visualize and quantify parasite development in Huh7 cells, a human hepatoma cell line. Eight seaweed 
extracts representing all three classes of marine macroalgae [green seaweeds Cladophora rupestris 
(CR), Codium fragile ssp. tomentosoides (CFsT), Ulva lactuca (UL); brown seaweeds Cystoseira 
baccata (CB), C. tamariscifolia (CT); red seaweeds Osmundea pinnatifida (OP), Ceramium virgatum 
(CV) and Halopitys incurvus (HI)], showed moderate activity against hepatic stage parasites with IC50 
values in the range of 14.9–52.9 μg/mL (Table 2). Figure 1 displays the growth inhibitory activity of 
these extracts in human hepatoma (Huh7) cells, which were infected with luciferase-expressing  
P. berghei sporozoites and treated at 3 h post infection (hpi) with 50 μg/mL concentrations of seaweed 
extracts, DMSO and the positive control primaquine. Notably, none of the active extracts had any 
obvious effect on Huh7 cell viability, as assayed by fluorescence intensity measurements after 
incubation with an active plasma membrane labeling dye, Alamar Blue (red line, Figure 1). 
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Intracellular localization of the LS parasites and the effect of the active extracts on the morphology and 
development of the LS parasites in Huh7 cells were studied by immunofluorescence analysis. Figure 2 
shows representative confocal images of exo-erythrocytic form (EEFs) parasites in cells that were 
treated with two active extracts (HI and UL, 50 μg/mL), fixed, and labeled with anti-PbHSP70  
(P. berghei heat shock protein 70, green). Both host cell and parasite nuclei were stained with Hoechst 
(blue). In accordance with the bioluminescence results, both extracts severely impaired the 
development of LS parasites, which was similar to that observed with 15 μM (=6.8 μg/mL) 
primaquine, the control drug. 
Figure 1. Inhibition of liver stage P. berghei infection by seaweed extracts at 50 μg/mL, 
determined by measurement of luciferase activity (bars, expressed as percentage of control) 
in PbGFP-Luccon-infected human hepatoma (Huh7) cells. Red line indicates the effect of 
the extracts on cell proliferation, assessed by fluorescence measurement of Huh7 cells at 
the time of analysis. Primaquine, positive control; DMSO-solvent-treated control. Error 
bars represent the standard deviations of three independent measurements. Abbreviations 
for the seaweed names can be found in Table 1. 
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Figure 2. Immunostaining of P. berghei exo-erythrocytic forms (EEFs) at 44 h post 
infection (hpi). Huh7 cells were seeded on glass coverslips and infected with P. berghei 
ANKA sporozoites. At 3 hpi, infected cells were treated with control DMSO, 50 μg/mL of 
seaweed extracts, Halopitys incurvus (HI) and Ulva lactuca (UL), or primaquine  
(15 μM = 6.8 μg/mL). EEFs were immunostained with mouse anti-Hsp70 (Alexa 488, 
green). Nuclei were stained with DAPI (blue). Confocal images were acquired using a 
ZEISS LSM 510 confocal microscope with a X63 oil objective. Scale bar: 10 μM. 
 
2.3. Plasmodial FAS-II Enzyme Inhibitory Activity of British Seaweeds 
The above-mentioned results on LS parasites encouraged us to search for potential drug targets of 
LS-active seaweed extract. We tested them, by using an established in vitro spectrophotometric  
assay [19], against three key elongation enzymes (PfFabI, PfFabG and PfFabZ) of the P. falciparum 
type-II fatty acid biosynthesis (FAS-II) pathway. These are small (18.9–45.3 kDa) enzymes prepared 
recombinantly in our laboratory as described [19] and belong to classes of reductases (PfFabI:  
Enoyl-ACP reductase, PfFabG: beta-ketoacyl-ACP reductase) and dehydratases (PfFabZ:  
Beta-hydroxyacyl-ACP dehydratase). The rationale for the selection of the enzymes was based on the 
fact that the PfFabI and PfFabZ enzymes are vital for pre-erythrocytic (liver) stage infection [6,7]. The 
PfFabG was also included, as its inhibition has been shown to cause anti-LS activity [9]. As depicted 
in Table 2, half of the extracts (brown: Cystoseira baccata (CB), C. tamariscifolia (CT), red: 
Ceramium virgatum (CV), Halopitys incurvus (HI), inhibited all three target enzymes (IC50 values  
DMSO 
HI 
UL 
Primaquine 
DAP
I 
Hsp7
0 
Merged 
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1.3–37 μg/mL). The green algae Cladophora rupestris (CR), Codium fragile ssp. tomentosoides 
(CFsT), and the red algae Osmundea pinnatifida (OP) and Claviclonium ovatum (ClO) inhibited only 
the dehydratase PfFabZ at low μg/mL doses (IC50 values 1.0–13 μg/mL). The crude extract of  
U. lactuca (UL) was the only one that inhibited both PfFabI and PfFabZ with IC50 values of 2 and  
7 μg/mL. 
Considering the serious concerns of drug resistance to BS antimalarials, and difficult-to-treat 
chronic liver stages, plus the need for a true causal prophylaxis, it is obvious that ideal malaria therapy 
should target both intracellular mammalian stages of the parasites. This study provided a simultaneous 
profiling of 23 seaweeds collected from British waters for both LS and BS activity in two different 
Plasmodium species in standardized conditions. The aim of this profiling was (i) to assess stage 
selectivity of the seaweed extracts, (ii) to discover new resources for the discovery of malaria 
prophylactic natural products that target LS, and (iii) most importantly, to find new natural resources 
that can possess dual stage activity against both stage parasites. More than half of the seaweed extracts 
studied here revealed good to moderate level of BS activity against human malaria parasite  
P. falciparum, whereas eight extracts impaired the LS cultures of rodent malaria parasite P. berghei. 
Eight extracts failed to kill either LS or BS parasites in vitro. The green alga U. intestinalis (UI), 
brown algae Sargassum muticum (SM), both Fucus species (FS, FV), Laminaria digitata (LD), 
Saccorhiza polyschides (SP), and red alga Corallina officinalis (CoO), inhibited BS parasites only, 
whereas Halopitys incurvus (HI) selectively targeted the LS parasites. Importantly, except for the latter 
extract, all extracts that displayed LS growth arrest also killed BS parasites, indicating that they are 
inhibitors of both intracellular stages of Plasmodium. Although the potency against LS is generally  
2- to 3-fold lower than that of BS activity, it is still significant that, for the very first time, LS activity 
is being detected in seaweed extracts. To the best of our knowledge, this is the first report of hepatic 
stage antiplasmodial activity and dual activity of any seaweed in the literature. The extracts with  
anti-LS activity inhibited one or more LS target enzymes of the FAS-II. Whether FAS-II could be 
considered as the ultimate target of the LS-active extracts is unclear at this stage, and needs to be 
further validated by metabolic studies to confirm the inhibition of parasitic fatty acid biosynthesis by 
the seaweed extracts. Importantly, the extracts do not show any significant toxicity on Huh7 cells or 
L6 cells, indicating selectivity, which is important for drug development. This is also the first study 
describing the BS antimalarial activity of British seaweeds. 
A detailed survey indicates that only a few recent screening studies have investigated the BS 
inhibitory activity of the seaweed extracts originating from Turkey, France, Egypt and  
India [13,14,20–24]. Some of the macroalgae tested in this study have been included in the previous 
studies, but the results are only partly in agreement with ours. The discrepancy might stem from the 
use of different strains of Plasmodium species and different methods. Two studies that have used the 
similar experimental conditions are worthy of mention. The first screening study performed on 
seaweeds collected from the Normandy coast (France) showed ethyl acetate extracts of red and brown 
seaweeds to be highly active against the multi-drug resistant K1 strain of P. falciparum [20]. The green 
algal extracts, including that of U. lactuca (UL) that appeared to be one of the most active extracts in 
the present work, were not active. In contrast, Dictyota dichotoma (DD), which was completely 
inactive in our study showed considerable activity (IC50 8.8 μg/mL). On the other hand, U. lactuca 
(UL) and C. barbata (CB) collected from Turkish waters revealed much lower activity against the 
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same K1 strain of P. falciparum (IC50 18.3 and 48.8 μg/mL, respectively) [13,15]. The discrepancy is 
likely to originate from the use of different solvents for extraction. Another major factor is the 
environment from which the seaweeds originate, as the environmental pressures shape the chemical 
composition, hence the biological activity of the marine organisms. This study reports the LS and/or 
BS activity of a few seaweed genera, e.g., Osmundea, Halopitys, Fucus and Saccorhiza for the  
first time. 
Limited studies have reported BS antiplasmodial activity of both primary and secondary 
metabolites obtained from marine macroalgae. Most of the antiplasmodial seaweed secondary 
metabolites belong to the class of terpenes, mainly isolated from red and brown algae. The examples 
include halogenated terpenes [25], brominated meroterpenes [26–28], tocopherol derivatives [27] and 
carotenoid-like compounds [29]. Interestingly, complex primary metabolites, such as sulfated 
polysaccharides were also shown to inhibit both drug-sensitive and drug-resistant strains of  
P. falciparum and the adhesion of parasitized erythrocytes to the human glycoprotein CD36 [30]. 
Fucoidan, another sulfated polysaccharide from the Korean brown seaweed Undaria pinnatifida 
inhibits the invasion of Plasmodium merozoites into erythrocytes in vitro and shows in vivo  
activity [31]. Large polysaccharides, e.g., fucoidan, also hinder the binding of sporozoites to the 
surface of hepatocytes and thus invasion into these cells [32]. Hence, it is intriguing to study both the 
LS and BS activity of our extracts to identify both primary and/or secondary metabolites responsible 
for the initial activity, and identify their mechanism(s) of actions. 
The malaria parasite Plasmodium has two distinct intracellular growth stages inside the human host. 
Despite taking place in two distinct cell types (LS in hepatocytes, BS in erythrocytes); having an 
orders-of-magnitude difference in parasite replication (LS ten thousands, BS trillions); the number of 
cycles (LS one cycle, BS multiple cycles) and length (LS generally 7 days, can be up to 14 days 
depending on Plasmodium species; whereas BS 1–3 days), the LS and BS have many common 
features. In both stages, the parasite forms a parasitophorous vacuole (PV) in which it grows and 
replicates safely [33]. Many metabolic pathways are presumably similar [9]. A recent screening 
identified several compounds with anti-LS activity, many of which inhibit similar metabolic pathways 
to BS targets, such as dihydrofolate reductase or cyctochrome bc1 complex [5]. Replication of the 
malaria parasites in the liver or in erythrocytes requires vast amounts of fatty acids (FA). Plasmodium 
was previously thought to acquire FAs by scavenging from the human host. However, the parasite was 
shown to be capable of type II fatty acid biosynthesis (FAS II) [34], whose enzymes are targeted to the 
apicoplast, a relict, non-photosynthetic plastid of red algal origin [35]. Interestingly, the pathway is 
only essential in the LS, mainly during the transition stage from LS to BS to initiate red blood cell 
infection [6,7]. Triclosan was previously reported to inhibit BS infections, in vitro and in vivo, through 
inhibition of PfFabI, a rate-limiting FAS-II enzyme. Triclosan is a potent PfFabI inhibitor, but its BS 
activity in rodent models was shown to be minimal [36]. It inhibits the late LS of Plasmodium [37]. 
Currently, it is not fully understood why the FAS-II pathway is necessary for the late LS, but it is 
probably due to requirement of a sheer amount of membrane biogenesis for the formation of very large 
numbers of merozoites in BS [7]. In this study we show that red algae, as well as other types of marine 
algae, are capable of inhibiting at least one algal-like PfFAS-II enzyme, and probably thereby impair 
the LS parasite growth. A multiple enzyme inhibition capacity is an advantage, as it will require much 
longer time for the parasite to introduce mutations, if any, hence bear a low/slow risk of resistance 
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development against the drug. The apicoplast harbors other plant-bacterial type pathways, such as  
non-mevalonate isoprene, lipoic acid and heme biosyntheses [38]. It would be intriguing to investigate 
whether the complex algae extracts inhibit these pathways as well. Potential drug targets for BS 
activity warrant further studies. 
It is now widely accepted that malaria control or eradication can only be achieved through a 
multidisciplinary approach, which requires research and investment in multiple developmental life 
stages of the parasite and evaluation of hitherto untapped sources, such as marine organisms. The 
results obtained in this study can be useful in several ways. First, it can further fuel investigations in 
finding seaweed metabolites than can cure BS malaria infections, in line with the traditional malaria 
drug discovery efforts. Secondly, seaweed extract(s) that selectively inhibit the LS only (e.g., HI) can 
be studied to identify natural products that provide true causal chemoprophylaxis. Such a strategy has 
certain advantages, e.g., low risk of resistance, due to low consumption rates of the compound and low 
numbers of parasites that exist during liver stages. Finally, seaweed extracts can be studied to reveal 
new metabolites with dual stage efficacy for both preventing and curing malaria infections. 
Compounds with multiple stage activity have the potential to be very beneficial for controlling the 
spread of disease in malaria endemic areas and for preventing disease in travelers to malarious regions. 
Malaria drug discovery from natural sources, particularly from marine organisms faces many 
obstacles, such as the minute yield of the active principles and the complexity of the chemical 
structures for synthesis. The use of seaweeds in drug discovery is more advantageous; as the supply 
issue is less problematic in comparison to that observed with other marine organisms (e.g., 
invertebrates). Furthermore, it is nowadays possible to cultivate seaweeds by using aqua- or 
mariculture to obtain larger amounts of the biomass and the bioactive compounds of interest. Hence, 
seaweeds merit intensive studies as source of highly efficacious, new and affordable lead molecules for 
prevention or therapy of malarial infections. 
3. Experimental Section 
3.1. Algal Material 
The algal material was collected from different locations along the south coast of England in 2007. 
Table 1 includes details on their origin and collection times. The samples were initially identified by 
one of the authors (GB) and verified by Dr. W.F. Farnham (Department of Biological Sciences, 
University of Portsmouth, Portsmouth, Hampshire, UK). Voucher samples of the algae are kept in the 
Herbarium of the Hampshire County Council Museums Service (available under Bi 2000.16) and  
at the School of Chemistry, National University of Ireland, Galway, Ireland (under voucher  
numbers GB07). 
3.2. Preparation of the Extracts 
Freshly collected algae (ca. 10–20 g wet weight) were soaked in i-PrOH (100 mL) and transported 
to the laboratory. Algal material was homogenized by a household blender and filtered. The residue 
was extracted overnight with CHCl3:MeOH mixtures (3:1 and 1:1, respectively) under continuous 
stirring at room temperature (rt) and combined with the i-PrOH extract obtained above. The combined 
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crude extract was dissolved in 10 mL EtOAc:MeOH (1:1) mixture and centrifuged. The supernatant 
was evaporated to dryness in vacuum at 30 °C and kept at −20 °C until used in the biological assays. 
3.3. Blood Stage Antiplasmodial Activity 
In vitro activity against erythrocytic stages of P. falciparum was determined by a modified  
[
3
H]-hypoxanthine incorporation assay [18], using the chloroquine- and pyrimethamine-resistant K1 
strain and the standard drug chloroquine. Briefly, parasite cultures incubated in RPMI 1640 medium 
with 5% Albumax (without hypoxanthine) were exposed to serial drug dilutions in microtiter plates. 
After 48 h of incubation at 37 °C in a reduced oxygen atmosphere, 0.5 μCi 3H-hypoxanthine was 
added to each well. Cultures were incubated for a further 24 h before they were harvested onto  
glass-fiber filters and washed with distilled water. The radioactivity was counted using a Betaplate
TM
 
liquid scintillation counter (Wallac, Zurich, Switzerland). The results were recorded as counts per 
minute (CPM) per well at each drug concentration and expressed as percentage of the untreated 
controls. IC50 values were calculated from graphically plotted dose-response curves by linear 
regression [39] using Microsoft Excel. The reported IC50 values are the means of at least two  
separate experiments. 
3.4. Liver Stage Antiplasmodial Activity 
3.4.1. Culturing and Infection of Huh7 Cells with P. berghei ANKA Sporozoites 
Human hepatoma cells (Huh7, 1–4 × 104) were seeded per well of a 96 well-plate or on glass 
coverslips in a 24 well-plate, respectively, and incubated overnight at 37 °C in a 5% CO2 incubator. 
Luciferase-expressing transgenic P. berghei sporozoites that were dissected from salivary glands of 
infected Anopheles stephensi mosquitoes were re-suspended in an appropriate volume of RPMI 1640 
medium supplemented with 10% Fetal Bovine Serum (FBS), 1% penicillin-streptomycin, 10mM 
HEPES, 1% glutamine, 1% non-essential amino acids, and 0.02% Fungizone. Ten to thirty thousand 
sporozoites were added to each well of 96- or 24-well plates (for luciferase or microscopy assays, 
respectively), followed by centrifugation at 3000 rpm for 5 min and incubation at 37 °C in a 5% CO2 
incubator for the duration of the experiment. 
3.4.2. In Vitro Testing of Liver Stage Antiplasmodial Activity of Seaweed Crude Extracts 
Three hours after infection, the seaweed extracts were diluted in complete culture medium to a final 
concentration of 50 μg/mL and added to infected cells for over 40 h with medium/crude extracts 
changes 24 h after infection. Dimethysulfoxide (DMSO, Sigma-Aldrich, Munich, Germany), at a final 
concentration of 1.15% was used as a negative control. Primaquine biphosphate (Sigma Aldrich, 
Munich, Germany) was the positive control. Antiplasmodial activity of seaweed crude extracts was 
assayed according to ref. [40]. Briefly, at the end of treatments, cells were rinsed twice with PBS and 
further incubated in 75 μL of 1× reconstituted firefly luciferase lysis buffer per well, with agitation for 
15–20 min at 400 rpm at rt. The plate was centrifuged at 1000 rpm for 5 min in order to pellet cellular 
debris. Thirty μL of lysate from each well was transferred into a well in a white 96 well plate (Corning 
Incorporated, Corning, NY, USA), followed by the addition of 50 μL of 0.2 mg/mL of D-luciferin. The 
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plate was agitated for 4 s and luminescence intensity was measured in a microplate plate reader 
(Infinite M200, Tecan, Group Ltd., Männedorf, Switzerland) for 100 ms at excitation and emission 
wavelengths of 530 nm and 590 nm respectively. The level of luciferase activity in drug-treated 
samples was expressed as a percentage of control. All measurements were run in triplicates. 
3.4.3. Immunofluorescence Detection of P. berghei Parasites in Extract- or Control-Treated  
Huh7 Cells 
For intracellular localization of P. berghei parasites in Huh7 cells by immunofluorescence,  
P. berghei-infected cells on glass cover slips that had been treated with 50 µg/mL of each seaweed 
extract (or DMSO (1.1%), as a negative control) were washed briefly with PBS and fixed immediately 
with 4% paraformaldehyde (PFA) for 14 min at rt. The cells were washed thrice with PBS for 5 min on 
a shaker and then incubated in 0.1 M glycine for 10 min to quench cellular autofluorescence. Cellular 
membranes were permeabilized by incubation in 0.1% saponin for 20 min at rt, followed by three 
washes with PBS. The cells were further incubated in blocking solution, 1% bovine serum albumin 
(BSA) with 0.05% saponin, for 1 h at rt. P. berghei parasites were stained with a parasite specific  
anti-Hsp70 (2E6) antibody at a 1:300 dilution for 1 h at rt, followed by three washes with blocking 
solution and further incubation in a 1:400 dilution of an anti-mouse Alexa 488 secondary antibody. A 
further three washes were carried out with blocking solution in the presence of a 1:1000 dilution DAPI. 
Cover slips were mounted on microscope slides with fluoremount. Confocal images were acquired 
using a laser scanning confocal microscope, LSM 510 META, with the following parameters: 
excitation with 405 nm, Band Pass (BP): 420 nm–480 nm, excitation with 488 nm, BP:  
505 nm–530 nm. Images were processed with freely available Image J software. 
3.4.4. Cell Viability 
The effect of crude extract (or DMSO as a negative control) on the viability of Huh7 cells was 
assayed by the Alamar Blue fluorescence method [41] prior to the lysis of infected Huh7 cells. Briefly, 
cells were incubated with a 1/20 dilution of Alamar Blue in complete RPMI 1640 medium for about 
90–120 min and the fluorescence intensity was measured at 595 nm in a microplate reader 
(InfiniteM200, Tecan, Group Ltd., Männedorf, Switzerland). 
3.5. Plasmodial FAS-II Enzyme Inhibition Assays 
Plasmodial FAS-II enzyme inhibitory assays were carried out (in duplicate) as previously  
described [19]. Briefly, all measurements were performed in 20 mM HEPES, pH 7.4, and 150 mM 
NaCl in a total volume of 1 mL and PfFabZ activity was measured at 263 nm for 2 min in the presence 
of 25 μM crotonoyl-CoA and 1 μg of enzyme. Reference compounds were triclosan (PfFabI) and  
(−)-epigallocatechin gallate (PfFabG, PfFabZ). 
3.6. General Cytotoxicity against Mammalian Cells 
Assays were performed in 96-well microtiter plates, each well containing 100 μL of RPMI 1640 
medium supplemented with 1% L-glutamine (200 mM) and 10% FBS, and 4 × 10
4
 L6 cells. Serial drug 
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dilutions of seven 3- were prepared. After 72 h of incubation the plates were 
inspected under an inverted microscope to assure growth of the controls and sterile conditions.  
Ten  of a resazurin solution (12.5 mg resazurin in 100 mL water) was added to each well and the 
plates incubated for another 2 h. The plates were read with a Spectramax Gemini XS microplate 
fluorometer using an excitation wavelength of 536 nm and an emission wavelength of 588 nm. Data 
were analyzed using the microplate reader software Softmax Pro. Podophyllotoxin was the  
control drug. 
4. Conclusions 
Due to the limited arsenal of antimalarials, it has become necessary to find novel compounds to 
target multiple life stages of the malaria parasite. The current study paves the way for high throughput 
screening of seaweeds, and is hoped to encourage research for exploitation of seaweeds in discovery of 
natural products acting as dual inhibitors of two key developmental stages. Our future studies will 
include chemical profiling of the active extracts by LC-MS-based dereplication techniques and 
purification/structure elucidation of the active metabolites with dual activity by employing  
activity-guided isolation procedure. Mechanism of action studies will also be performed to identify 
common and/or specific drug targets of these compounds in both stages. 
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